|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
gptkb:drug
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2012
|
|
gptkbp:benefits
|
weight loss
lowering blood sugar
cardiovascular risk reduction
|
|
gptkbp:brand
|
gptkb:Farxiga
|
|
gptkbp:clinical_trial
|
combination therapy
Phase III
monotherapy
|
|
gptkbp:contraindication
|
severe renal impairment
history of serious hypersensitivity reactions
|
|
gptkbp:discovered_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
5 mg tablet
10 mg tablet
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dapagliflozin propanediol
|
|
gptkbp:ingredients
|
C21 H25 Cl O6 S
|
|
gptkbp:interacts_with
|
gptkb:Company
diuretics
sulfonylureas
|
|
gptkbp:is_atype_of
|
A10 B K03
|
|
gptkbp:is_used_for
|
treatment of type 2 diabetes
|
|
gptkbp:lifespan
|
12.9 hours
|
|
gptkbp:metabolism
|
primarily hepatic
|
|
gptkbp:population
|
adults with type 2 diabetes
|
|
gptkbp:related_to
|
canagliflozin
empagliflozin
ertugliflozin
|
|
gptkbp:release_region
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:safety_features
|
risk of bone fractures
risk of hypotension
risk of ketoacidosis
risk of acute kidney injury
risk of dehydration
|
|
gptkbp:side_effect
|
dehydration
urinary tract infections
genital mycotic infections
|
|
gptkbp:type_of
|
461432-26-8
|
|
gptkbp:bfsParent
|
gptkb:dapagliflozin
|
|
gptkbp:bfsLayer
|
5
|